Risk of overall and site-specific cancers in Behçet disease: A nationwide population-based study in Taiwan

Journal of Rheumatology

Volumn 42, Issue 5, 2015, Pages 879-884

  Wang, Li Hui ^a   Wang, Wei Ming ^b   Hsu, Sheng Min ^c   Lin, Sheng Hsiang ^d   Shieh, Chi Chang ^c,e  

^a KUO GENERAL HOSPITAL   (Taiwan)

^b OMC Clinical Research Center   (United States)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Beh et disease; Breast cancer; Cancer risk; Hematological malignancy; Lymphoma

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER LOCALIZATION; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE DURATION; EYE CANCER; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; ICD-9; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; NONHODGKIN LYMPHOMA; PENIS CANCER; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; SCROTUM DISORDER; SKIN CANCER; TAIWAN; TESTIS CANCER; VAGINA CANCER; VULVA CANCER; AGED; BEHCET SYNDROME; COMPLICATION; FACTUAL DATABASE; INCIDENCE; MIDDLE AGED; NEOPLASMS; RISK; RISK ASSESSMENT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BEHCET SYNDROME; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RISK; RISK ASSESSMENT; TAIWAN; YOUNG ADULT;

EID: 84940479477     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140770     Document Type: Article

References (34)

1. Reynolds N. Vasculitis in Behcet's syndrome: evidence-based review. Curr Opin Rheumatol 2008;20:347-52.
2. Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a double-edged sword. Cancer Cell 2007;12:300-1.
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
5. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-27.
6. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71.
7. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
8. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-33.
9. Chen YJ, Chang YT, Wang CB, Wu CY. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum 2011;63:352-8.
10. Liang JA, Sun LM, Yeh JJ, Lin WY, Chang SN, Sung HC, et al. Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study. Rheumatol Int 2012;32:773-8.
11. Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 2011;165:1273-9.
12. Weng MY, Huang YT, Liu MF, Lu TH. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan. Ann Rheum Dis 2012;71:524-7.
13. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005;52:2415-24.
14. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 2003;82:60-76.
15. Ahn JK, Oh JM, Lee J, Koh EM, Cha HS. Behcet's disease associated with malignancy in Korea: a single center experience. Rheumatol Int 2010;30:831-5.
16. Na SY, Shin J, Lee ES. Morbidity of solid cancer in Behçet's disease: analysis of 11 cases in a series of 506 patients. Yonsei Med J 2013;54:895-901.
17. Lin Y, Li G, Zheng W, Tian X, Zhang F. Behcet's disease associated with malignancy: a report of 41 Chinese cases. Int J Rheum Dis 2014;17:459-65.
18. Cengiz M, Altundag MK, Zorlu AF, Gullu IH, Ozyar E, Atahan IL. Malignancy in Behcet's disease: a report of 13 cases and a review of the literature. Clin Rheumatol 2001;20:239-44.
19. Kaklamani VG, Tzonou A, Kaklamanis PG. Behçet's disease associated with malignancies. Report of two cases and review of the literature. Clin Exp Rheumatol 2005;23 Suppl 38:S35-41.
20. Yeh HY, Wu JC, Haschler I, Chen TJ, Wetter T. Taiwan's National Health Insurance Research Database: administrative health care database as study object in bibliometrics. Scientometrics 2011;86:365-80.
21. National Health Insurance Administration. Catastrophic illness patients. [Internet. February 25, 2015. ] Available from: www. nhi. gov. tw/English/webdata/webdata. aspx?menu=11&menu -id=596&WD-ID=596&webdata-id=3180
22. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
23. Columbia University Mailman School of Public Health. Cohort study: standardized incidence ratio (SIR). [Internet. Accessed February 25, 2015. ] Available from: epiville. ccnmtl. columbia. edu/99interactive/sir. html
24. Merrill RM, Timmreck TC. Design strategies and statistical methods in descriptive epidemiology. Introduction to epidemiology. Sudbury: Jones & Bartlett Publishers; 2006:90-1.
25. Taiwan Cancer Registry. Department of Health. [Internet. Accessed February 25, 2015. ] Available from: tcr. cph. ntu. edu. tw/main. php?Page=N1
26. Greenland S, Rothman KJ. Fundamentals of epidemiology data analysis. In: Rothman KJ, Greenland S, Lash TL, eds. Modern epidemiology. Philadelphia: Lippincott Williams & Wilkins; 2008:213-37.
27. Kitaichi N, Miyazaki A, Stanford MR, Iwata D, Chams H, Ohno S. Low prevalence of juvenile-onset Behcet's disease with uveitis in East/South Asian people. Br J Ophthalmol 2009;93:1428-30.
28. Yurdakul S, Yazici H. Behcet's syndrome. Best Pract Res Clin Rheumatol 2008;22:793-809.
29. Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. Arthritis Rheum 2009; 61:600-4.
30. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders-what are the driving forces? Semin Cancer Biol 2014;24:61-70.
31. Martin DN, Mikhail IS, Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 2009;50:541-50.
32. Cil AP, Karabulut AA, Koçak M. Assessment of ovarian stromal artery Doppler characteristics and serum hormone levels in patients with Behçet disease. Diagn Interv Radiol 2010;16:288-92.
33. Proença H, Ferreira C, Miranda M, Castanheira-Dinis A, Monteiro-Grillo M. Serum prolactin levels and Behcet disease. Eur J Ophthalmol 2007;17:404-7.
34. Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, et al. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 2013;73:4810-9.